达雷妥尤单抗治疗免疫性血小板减少症的安全性与疗效
这项多中心、开放标签、2期研究评估达雷妥尤单抗治疗21例经治免疫性血小板减少症(ITP)患者的安全性与疗效。皮下注射1800 mg达雷妥尤单抗后,10例(48%)达到主要疗效终点,8例(38%)获得持续应答;大多数治疗中出现的不良事件为短暂1至2级,最常见为感染(38%)。
要点
- 21例经治ITP患者接受皮下达雷妥尤单抗1800 mg,10例(48%)达到主要疗效终点。
- 8例(38%)获得持续应答,其中2例 later 复发;两个队列的应答率和复发率无差异。
- 大多数治疗中出现的不良事件为短暂1至2级,最常见为感染(38%)。
核心结论
- 本研究证实CD38是ITP的重要治疗靶点,达雷妥尤单抗在经治ITP患者中显示出疗效和可管理的安全性。
研究设计与样本
- 多中心、开放标签、2期研究,纳入21例既往接受过治疗的ITP患者。
- 安全性导入后设2个给药队列,分别接受8次和10次皮下注射达雷妥尤单抗1800 mg,每周一次。
- 主要终点为安全性和应答(安全性导入/队列1在第12周、队列2在第16周连续2次血小板计数≥50 × 109/L)。
主要发现
- 基线中位血小板计数为17 × 109/L,中位既往治疗数为4。
- 10例患者(48%)达到主要疗效终点。
- 8例患者(38%)获得持续应答(第24周连续2次血小板计数≥50 × 109/L),其中2例 later 复发。
- 两个队列的应答率和复发率无差异。
- 应答患者中通过36项简短健康调查量表测定的患者报告生活质量改善。
关键数值与推荐
- 主要疗效终点:安全性导入/队列1在第12周、队列2在第16周连续2次血小板计数≥50 × 109/L。
- 持续应答:第24周连续2次血小板计数≥50 × 109/L。
- 大多数治疗中出现的不良事件为短暂1至2级,最常见为感染(38%)。
- 2例患者(4.7%)发生3级不良事件,分别为1例输注相关反应和1例严重急性呼吸综合征冠状病毒2感染伴急性肾衰竭。
临床怎么用
- 达雷妥尤单抗降低所有患者的免疫球蛋白水平,并大幅减少外周血和骨髓中的CD38+细胞。
- 应答者与无应答者之间的抗血小板抗体无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to B-cell-targeted therapies in immune thrombocytopenia (ITP) has been linked to persistence of autoantibody-producing CD38+ long-lived plasma cells. CD38 antibody daratumumab has been proposed as a potential therapy for ITP. This multicenter, open-label, phase 2 study evaluated safety and efficacy of daratumumab in 21 patients with previously treated ITP. Following a safety run-in, 2 dosing cohorts received 8 and 10 subcutaneous injections of 1800 mg daratumumab weekly, respectively. Primary end points were safety and response (2 consecutive platelet counts ≥50 × 109/L at week 12 for the safety run-in/cohort 1, and at week 16 for cohort 2). At baseline, median platelet count was 17 × 109/L, median number of prior therapies was 4. Most treatment-emergent adverse events were transient grade 1 to 2, most commonly infections (38%). Two patients (4.7%) experienced grade 3 adverse events, 1 infusion-related reaction, and 1 severe acute respiratory syndrome coronavirus 2 infection with acute renal failure. Ten patients (48%) met the primary efficacy end point. Sustained response (2 consecutive platelet counts ≥50 × 109/L at week 24) was achieved in 8 patients (38%), of whom 2 later relapsed. Response and relapse rates did not differ between cohorts. Patient-reported quality of life measured by 36-Item Short-Form Health Survey improved in responding patients. Daratumumab decreased immunoglobulin levels in all patients, and substantially reduced CD38+ cells in peripheral blood and bone marrow. There was no significant difference in antiplatelet antibodies between responders and nonresponders. This study confirms CD38 as an important target in ITP. This trial was registered at clinicaltrials.gov as #NCT04703621, and at the European Clinical Trial Register (EudraCT #2019-004683-22).
引用
- Tsykunova G, Holme PA, Tran HTT, et al. Safety and efficacy of daratumumab in immune thrombocytopenia. Blood Adv. 2026. PMID: 40763272. doi:10.1182/bloodadvances.2025017279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。